Firms join in new IMI adaptive pathways project
This article was originally published in Scrip
Executive Summary
The EU's Innovative Medicines Initiative (IMI) is about to launch a new collaborative public-private project looking at how best to co-ordinate and support activities being conducted in the area of adaptive pathways, with a view to producing a comprehensive plan for developing and using relevant tools and methodologies throughout the product life cycle.
You may also be interested in...
High Expectations From EU’s ‘Neutral’ Hub On Real-World Evidence
The Netherlands-based GetReal Institute builds on seven years of multi-stakeholder collaboration to promote greater understanding of real-world evidence.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.